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that of physicians’ preferences for middle-aged patients across
most beneﬁt levels. Compared to adult patients, parents have
greater risk tolerance for treating severe CD symptoms, and
smaller risk tolerance for treating moderate CD symptoms.CON-
CLUSION: Respondents indicated they are willing to accept
deﬁned mortality risks in exchange for clinical efﬁcacy and that
acceptance is affected by the degree of beneﬁt, the patient’s
characteristics and the nature of the SAE. Understanding risk-
beneﬁt preferences can assist in identifying appropriate treat-
ments and in informing welfare-enhancing regulatory decisions.
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OBJECTIVES: Back pain has a considerable impact on HRQoL,
even with new medications, treatments and guidelines the degree
of suffering for patients is high. The objective was to compare
HRQoL for patients with back pain in Germany for three
different treatment groups (guideline-, non-guideline- and self-
treatment-group). METHODS: Patients were consecutively
recruited by physicians in general practice (n = 54) in 2005.
Patients were categorized into the three groups according to
pre-speciﬁed algorithms. All groups completed the generic SF-36,
and the disease speciﬁc FFbH, von Korff Index and PHQ-D
questionnaires. In addition, a retrospective chart review was
conducted. HRQoL data was compared between the groups.
RESULTS: A total of 145 patients took part in this study
(n = 29 guideline-group, 44 non-guideline-group, 72 with self-
treatment). Patients in the self-treatment-group were younger
than patients in guideline- or non-guideline-group (49.8 vs. 59.4
vs 57. 4 years, p = 0.0021). The groups did not differ signiﬁcantly
in gender or other socio-demographic characteristics. The von
Korff Index was lowest (i.e. poorer) in the self-treatment-group
and highest in the guideline-group (p = 0.0077). Regarding
SF-36, patients in the guideline-group had the lowest physical
(30.2  8.5) and mental (41.2  13.5) component scores, only
the differences regarding physical component were statistically
signiﬁcant between the groups (p < 0.0001), those regarding
mental component were not (p = 0.2875). Regarding PHQ-D
items, the groups did not differ in frequency of major depressive
and other depressive symptoms. The guideline-group had signiﬁ-
cantly higher burden of somatoform symptoms compared to the
other two groups (p = 0.0219). The self-treatment-group had the
highest FFbH-R total score (67.7  21.5) compared to other two
groups (p = 0.0056). CONCLUSION: From the here collected
data, it seems that patients who are treated according to guide-
lines have reached a higher degree of suffering (poorer HRQoL)
compared to those patients with either treated without guidelines
and/or treat themselves. Further research is warranted to conﬁrm
our ﬁndings.
PODIUM SESSION II: CANCER
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OBJECTIVES: Translation of PRO measures is an essential com-
ponent of research methodology in preparation for multinational
clinical trials. The FACT-Neurotoxicity (FACT-Ntx) is used to
evaluate the quality of life of cancer patients suffering from
neurotoxicity, a side effect of certain treatments. This study set
out to linguistically validate the FACT-Ntx for use in Denmark,
India, Lithuania and South Africa. METHODS: The study
sample consisted of 176 patients (96 males and 80 females), with
varying cancer diagnoses and a mean age of 51 years, speaking
11 languages: Afrikaans (15), Danish (25), Gujarati (15), Hindi
(15), Kannada (15), Lithuanian (15), Malayalam (15), Marathi
(15), Punjabi (15), Tamil (15) and Telugu (16). The FACT-Ntx
was translated according to standard FACIT methodology.
Patients diagnosed with any stage cancer on any treatment and
experiencing neurotoxicity completed the respective translated
version and then participated in cognitive debrieﬁng interviews.
Statistical analyses (descriptive statistics, one-way ANOVA and
reliability analyses) were performed on the quantitative data.
Participant comments were analyzed qualitatively. RESULTS:
The FACT-Ntx translations showed good reliability and linguis-
tic validity. The internal consistency of all languages combined
was 0.86, and all items correlated at an acceptable level. In
general, the Ntx score differed across self-reported Performance
Status Rating (PSR) groups (nonparametric Kruskal-Wallis test
p < 0.0001). A nonparametric Generalized Linear Model (GLM)
approach (with multiple comparison adjusted signiﬁcance level
0.017) showed a difference between ‘PSR = 0’ and ‘PSR = 1’
(p = 0.0002) and a difference between ‘PSR = 0’ and ‘PSR = 2’
(p < 0.0001), both with ‘PSR = 0’ patients reporting less neuro-
toxicity. CONCLUSION: The FACT-Ntx has shown acceptable
reliability and linguistic validity in 11 languages. The instrument
has also shown adequate sensitivity in differentiating patients
with no symptoms and normal activity from patients reporting
some symptoms. We consider these translations acceptable for
use in international research and clinical trials.
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OBJECTIVES: To facilitate the comparison of net beneﬁts of
cancer treatments in clinical trials by developing and validating
a system to convert data from a QoL instrument into precise
and optimally weighted global QoL measures and utilities.
METHODS: Two-hundred cancer patients completed the Utility-
Based Questionnaire-Cancer (UBQ-C), a validated 34-item
cancer-speciﬁc instrument which includes scales of health status,
overall QoL, disabilities and distresses. Patients were interviewed
to elicit time trade-off (TTO) utilities for their own health states.
A global QoL measure was derived from a weighted combination
of the UBQ-C scales based on linear regression of health status
on the individual scales. An equation to convert global QoL into
utility was derived. Validity was examined using baseline data
from a RCT of advanced breast cancer chemotherapy (n = 290).
RESULTS: The weighted global QoL measure was more precise
than the single-item QoL scales. Median scores (IQR) were much
lower for the weighted global QoL measure: 0.77 (0.65, 0.85)
than for the direct TTO utility: 0.98 (0.85, 1.0). The best model
to predict utility from weighted global QoL was a power
transformation: TTO = 1-(1-global QoL)2.1. The measures dis-
criminated between RCT subjects with good and poor per-
formance status: mean (95% CI) derived utility scores for
ECOG 0-1 = 0.91 (0.89, 0.92), ECOG 2-3 = 0.75 (0.68, 0.81),
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